Asklepion Pharmaceuticals
CompanyUnited States
Asklepion Pharmaceuticals develops one asset, in phase 3 (citrulline in acute lung injury). Mostly small molecule; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 3
- 7
- Trials
- 2
- Signals
Pipeline
1Provides a precursor for arginine synthesis, supporting nitric oxide production and vasodilation.
Phase 3, Small molecule, acute lung injury, atrioventricular septal defect
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials7
- Signals20
- Similar companies6